DAY ONE BIOPHARMACEUTICALS I (DAWN) Forecast, Price Target & Analyst Ratings

NASDAQ:DAWN • US23954D1090

Current stock price

21.46 USD
-0.01 (-0.05%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DAY ONE BIOPHARMACEUTICALS I (DAWN).

Forecast Snapshot

Consensus Price Target

Price Target
$21.17
-1.37% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 1, 2026
Period
Q1 / 2026
EPS Estimate
-$0.29
Revenue Estimate
55.398M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
52.31%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$21.17
Upside
-1.37%
From current price of $21.46 to mean target of $21.17, Based on 13 analyst forecasts
Low
$17.17
Median
$21.93
High
$22.58

Price Target Revisions

1 Month
-10.27%
3 Months
-6.74%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for DAWN. The average price target is 21.17 USD. This implies a price decrease of -1.37% is expected in the next year compared to the current price of 21.46.
The average price target has been revised downward by 6.74% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

DAWN Current Analyst RatingDAWN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

DAWN Historical Analyst RatingsDAWN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
52.31%
DAWN was analyzed by 13 analysts. The buy percentage consensus is at 52. So analysts seem to be rather neutral about DAWN.
In the last month the buy percentage fell by 31 points. So the trust of analysts is decreasing.
DAWN was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11JP MorganDowngrade Overweight -> Neutral
2026-03-10HC Wainwright & Co.Downgrade Buy -> Neutral
2026-03-09WedbushDowngrade Outperform -> Neutral
2026-03-06Jones TradingDowngrade Buy -> Hold
2026-03-06NeedhamDowngrade Buy -> Hold
2026-02-25NeedhamMaintains Buy -> Buy
2026-02-25WedbushMaintains Outperform -> Outperform
2026-02-25HC Wainwright & Co.Maintains Buy -> Buy
2026-01-13TD CowenInitiate Buy
2025-11-24NeedhamReiterate Buy -> Buy
2025-11-24HC Wainwright & Co.Reiterate Buy -> Buy
2025-11-07JP MorganMaintains Overweight -> Overweight
2025-11-05Piper SandlerMaintains Overweight -> Overweight
2025-08-06NeedhamMaintains Buy -> Buy
2025-08-06HC Wainwright & Co.Maintains Buy -> Buy
2025-05-07NeedhamMaintains Buy -> Buy
2025-04-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-25Goldman SachsMaintains Buy -> Buy
2025-03-05JP MorganMaintains Overweight -> Overweight
2025-02-26NeedhamReiterate Buy -> Buy
2025-02-26WedbushReiterate Outperform -> Outperform
2025-02-26HC Wainwright & Co.Maintains Buy -> Buy
2025-02-10Goldman SachsMaintains Buy -> Buy
2025-01-13NeedhamReiterate Buy -> Buy
2025-01-07B of A SecuritiesMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 1, 2026
Period
Q1 / 2026
EPS Estimate
-$0.29
Revenue Estimate
55.398M
Revenue Q2Q
80.09%
EPS Q2Q
17.75%
Number of Analysts
11

Next Earnings Revisions

Revenue (1 Month)
-1.04%
Revenue (3 Months)
6.82%
EPS (1 Month)
-0.34%
EPS (3 Months)
9.64%

Next Earnings Summary

DAWN is expected to report earnings on 5/1/2026. The consensus EPS estimate for the next earnings is -0.29 USD and the consensus revenue estimate is 55.40M USD.
The next earnings revenue estimate has been revised upward by 6.82% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
DAWN revenue by date.DAWN revenue by date.
131.161M158.182M
20.60%		245.23M
55.03%		314.2M
28.12%		406.68M
29.43%		543.58M
33.66%		650.07M
19.59%		784.75M
20.72%		744.36M
-5.15%		803.34M
7.92%
EBITDA
YoY % growth
DAWN ebitda by date.DAWN ebitda by date.
-206.028M
-40.30%		-215.708M
-4.70%		-124.274M
42.39%		-77.719M
37.46%		-24.516M
68.46%		-21.42M
12.63%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
DAWN ebit by date.DAWN ebit by date.
-206.064M
-40.27%		-217.27M
-5.44%		-127.75M
41.20%		-102.175M
20.02%		-38.932M
61.90%		55.399M
242.30%		173.17M
212.59%		258.75M
49.42%		318.32M
23.02%		369.26M
16.00%		403.75M
9.34%
Operating Margin
DAWN operating margin by date.DAWN operating margin by date.
N/A-165.65%-80.76%-41.67%-12.39%13.62%31.86%39.80%40.56%49.61%50.26%
EPS
YoY % growth
DAWN eps by date.DAWN eps by date.
-2.38
-9.68%		-1.78
25.21%		-1.04
41.57%		-0.89
14.27%		-0.20
77.98%		0.25
226.41%		1.34
439.39%		1.96
46.48%		1.84
-6.11%		2.14
16.07%		2.32
8.35%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.29
17.75%		-0.19
35.91%		-0.17
9.33%		-0.16
23.20%		-0.18
36.22%		-0.17
6.71%		-0.14
17.11%		-0.14
11.45%
Revenue
Q2Q % growth		55.398M
80.09%		58.271M
71.85%		62.892M
58.04%		68.686M
27.86%		75.684M
36.62%		79.152M
35.83%		85.578M
36.07%		88.944M
29.49%
EBITDA
Q2Q % growth		-23.103M
42.60%		-19.513M
41.35%		-16.575M
23.48%		-12.617M
47.39%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-22.555M
45.08%		-20.883M
40.29%		-18.607M
23.27%		-15.582M
43.25%		-21.93M
2.77%		-21.522M
-3.06%		-18.258M
1.88%		-17.748M
-13.90%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 -3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
30.82%
EPS Next 5 Year
31.19%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
37.51%
Revenue Next 5 Year
32.96%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
22.32%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

DAY ONE BIOPHARMACEUTICALS I / DAWN Forecast FAQ

Can you provide the average price target for DAY ONE BIOPHARMACEUTICALS I stock?

13 analysts have analysed DAWN and the average price target is 21.17 USD. This implies a price decrease of -1.37% is expected in the next year compared to the current price of 21.46.

What is the next earnings date for DAWN stock?

DAY ONE BIOPHARMACEUTICALS I (DAWN) will report earnings on 2026-05-01.

What are the consensus estimates for DAY ONE BIOPHARMACEUTICALS I (DAWN) next earnings?

The consensus EPS estimate for the next earnings of DAY ONE BIOPHARMACEUTICALS I (DAWN) is -0.29 USD and the consensus revenue estimate is 55.40M USD.

What is the consensus rating for DAWN stock?

The consensus rating for DAY ONE BIOPHARMACEUTICALS I (DAWN) is 52.3077 / 100 . This indicates that analysts generally have a neutral outlook on the stock.